US FDA approves Adcirca for pulmonary arterial hypertension
This article was originally published in Scrip
Executive Summary
The US FDA has approved United Therapeutics' Adcirca (tadalafil) as a once-daily treatment for pulmonary arterial hypertension (PAH). The drug, which has been licensed from Lilly, is scheduled to be launched in August.